檢索結果 - Chen‐Ta Chi

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

    Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma 由 Chi-Jung Wu, Pei‐Chang Lee, Ya‐Wen Hung, Chieh-Ju Lee, Chen‐Ta Chi, I‐Cheng Lee, Ming‐Chih Hou, Yi‐Hsiang Huang

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria

    Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria 由 Ya-Wen Hung, I-Cheng Lee, Chen-Ta Chi, Rheun‐Chuan Lee, Chien-An Liu, Nai‐Chi Chiu, Hsuen-En Hwang, Yee Chao, Ming-Chih Hou, Yi‐Hsiang Huang

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy

    Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy 由 Hsien-Chen Mon, Pei‐Chang Lee, Yi‐Ping Hung, Ya‐Wen Hung, Chi-Jung Wu, Chieh-Ju Lee, Chen‐Ta Chi, I‐Cheng Lee, Ming‐Chih Hou, Yi‐Hsiang Huang

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

    Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma 由 Pei‐Chang Lee, Chi-Jung Wu, Ya‐Wen Hung, Chieh Ju Lee, Chen‐Ta Chi, I‐Cheng Lee, Yu‐Lun Kuo, Shih-Hsuan Chou, Jiing‐Chyuan Luo, Ming‐Chih Hou, Yi‐Hsiang Huang

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: